Skip to content

Escalon Medical Corp.: 10-Q filed 2025-02-14

What Escalon Medical Corp. reported in its quarterly report filed 2025-02-14 (fiscal Q2 2025): 35 published measures, 100 facts as tagged in accession 0000862668-25-000006.

This filing

Form
10-Q (quarterly report)
Filed
2025-02-14
Fiscal period
fiscal Q2 2025
Accession
0000862668-25-000006 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Escalon Medical Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-314,486,501USD
At 2024-06-304,757,925USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-12-312,463,115USD
At 2024-06-302,948,343USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-312,023,386USD
At 2024-09-301,777,365USD
At 2024-06-301,809,582USD
At 2023-12-311,837,325USD
At 2023-09-301,913,646USD
At 2023-06-301,934,843USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-31246,021USD92
2024-07-01 to 2024-12-31213,804USD184
2024-07-01 to 2024-09-30-32,217USD92
2023-10-01 to 2023-12-31-76,321USD92
2023-07-01 to 2023-12-31-97,518USD184
2023-07-01 to 2023-09-30-21,197USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2024-12-31334,270USD184
2023-07-01 to 2023-12-31-438,090USD184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-07-01 to 2024-12-310USD184
2023-07-01 to 2023-12-3140,286USD184

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-10-01 to 2024-12-313,220,556USD92
2024-07-01 to 2024-12-316,001,902USD184
2023-10-01 to 2023-12-312,869,237USD92
2023-07-01 to 2023-12-315,814,237USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2024-12-31-22,655USD184
2023-07-01 to 2023-12-31-20,792USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-07-01 to 2024-12-310USD184
2023-07-01 to 2023-12-31-40,286USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-68,331,072USD
At 2024-06-30-68,544,876USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-10-01 to 2024-12-317,415,329shares92
2024-07-01 to 2024-12-317,415,329shares184
2023-10-01 to 2023-12-317,415,329shares92
2023-07-01 to 2023-12-317,415,329shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-10-01 to 2024-12-3114,081,616shares92
2024-07-01 to 2024-12-3114,081,616shares184
2023-10-01 to 2023-12-317,415,329shares92
2023-07-01 to 2023-12-317,415,329shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-10-01 to 2024-12-310.02USD/shares92
2024-07-01 to 2024-12-310.01USD/shares184
2023-10-01 to 2023-12-31-0.01USD/shares92
2023-07-01 to 2023-12-31-0.02USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-10-01 to 2024-12-310.02USD/shares92
2024-07-01 to 2024-12-310.01USD/shares184
2023-10-01 to 2023-12-31-0.01USD/shares92
2023-07-01 to 2023-12-31-0.02USD/shares184

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-10-01 to 2024-12-310USD92
2024-07-01 to 2024-12-310USD184
2023-10-01 to 2023-12-310USD92
2023-07-01 to 2023-12-310USD184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-12-3138,224USD
At 2024-06-3048,878USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-10-01 to 2024-12-31255,904USD92
2024-07-01 to 2024-12-31228,949USD184
2023-10-01 to 2023-12-31-70,524USD92
2023-07-01 to 2023-12-31-86,171USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-12-314,303,550USD
At 2024-06-304,396,828USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-312,211,277USD
At 2024-06-302,668,939USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-12-31891,782USD
At 2024-06-301,357,222USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-12-3139,617USD
At 2024-06-3049,442USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-12-311,719,083USD
At 2024-06-301,613,118USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-10-01 to 2024-12-311,162,137USD92
2024-07-01 to 2024-12-312,261,391USD184
2023-10-01 to 2023-12-311,184,236USD92
2023-07-01 to 2023-12-312,284,368USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-10-01 to 2024-12-31155,940USD92
2024-07-01 to 2024-12-31296,799USD184
2023-10-01 to 2023-12-31147,715USD92
2023-07-01 to 2023-12-31359,365USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-317,415,329shares
At 2024-06-307,415,329shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-12-31777,070USD
At 2024-06-30465,455USD
At 2023-12-31646,799USD
At 2023-06-301,145,967USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-12-3169,702,043USD
At 2024-06-3069,702,043USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-3142,322USD
At 2024-06-30199,989USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-12-31704,627USD
At 2024-06-30588,317USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-10-01 to 2024-12-31122,724USD92
2024-07-01 to 2024-12-3198,929USD184
2023-10-01 to 2023-12-31-89,327USD92
2023-07-01 to 2023-12-31-123,530USD184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-07-01 to 2024-12-3120,479USD184
2023-07-01 to 2023-12-3123,180USD184

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-07-01 to 2024-12-3111,464USD184
2023-07-01 to 2023-12-3111,413USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-31-513,411USD184
2023-07-01 to 2023-12-31270,790USD184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-31105,965USD184
2023-07-01 to 2023-12-31-180,444USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-31-465,440USD184
2023-07-01 to 2023-12-31-218,001USD184

Inspect the source

Entity
Escalon Medical Corp. / CIK 0000862668
Captured
2026-09-20T04:59:43.148Z
SEC response SHA-256
1553c3790334a15d4c4528d0e1ce16eac37d12130ed9cd66f6b338c07ce2533d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000862668.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))